Solventum (NYSE:SOLV) Issues FY 2025 Earnings Guidance

Solventum (NYSE:SOLV) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 5.980-6.080 for the period, compared to the consensus EPS estimate of 5.950. The company issued revenue guidance of -.

Solventum Trading Down 2.1%

NYSE:SOLV traded down $1.44 on Thursday, hitting $66.25. The stock had a trading volume of 1,791,817 shares, compared to its average volume of 876,666. The company has a fifty day moving average price of $72.00 and a two-hundred day moving average price of $72.33. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14. Solventum has a 1-year low of $60.70 and a 1-year high of $85.92. The stock has a market cap of $11.49 billion, a price-to-earnings ratio of 30.67, a PEG ratio of 2.75 and a beta of 0.48.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping the consensus estimate of $1.43 by $0.07. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The firm had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.05 billion. During the same period in the prior year, the business posted $1.64 EPS. The business’s revenue for the quarter was up .7% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Equities research analysts expect that Solventum will post 6.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on SOLV. Jefferies Financial Group began coverage on shares of Solventum in a research note on Thursday, September 11th. They issued a “hold” rating and a $80.00 price objective for the company. Wells Fargo & Company raised their price objective on shares of Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research note on Monday, September 15th. Wall Street Zen downgraded shares of Solventum from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. UBS Group initiated coverage on shares of Solventum in a report on Wednesday, October 1st. They set a “neutral” rating and a $77.00 price target for the company. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Solventum has a consensus rating of “Hold” and an average price target of $84.89.

Hedge Funds Weigh In On Solventum

Several institutional investors have recently modified their holdings of the company. United Services Automobile Association acquired a new position in Solventum during the first quarter valued at approximately $239,000. Woodline Partners LP grew its holdings in Solventum by 40.7% during the first quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock valued at $888,000 after purchasing an additional 3,377 shares during the last quarter. Intech Investment Management LLC grew its holdings in Solventum by 167.0% during the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock valued at $1,268,000 after purchasing an additional 10,425 shares during the last quarter. First Trust Advisors LP grew its holdings in Solventum by 5.8% during the second quarter. First Trust Advisors LP now owns 257,727 shares of the company’s stock valued at $19,546,000 after purchasing an additional 14,151 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in Solventum during the second quarter valued at approximately $766,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.